Sarepta Therapeutics Names Jean-Paul Kress To Board
This article was originally published in Scrip
Sarepta Therapeutics, a company developing RNA-targeted therapies, has appointed Jean-Paul Kress to its board of directors. Kress is currently head of Sanofi Genzyme speciality care business unit in North America and before this he was president and CEO of Sanofi Pasteur MSD.Previously, Kress was at Gilead as vice-president and general manager in France.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.